Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

Recent & Breaking News (TSX:ONC)

Oncolytics Biotech® Announces Annual General Meeting

PR Newswire April 30, 2021

Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting

Canada NewsWire April 29, 2021

Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study

Canada NewsWire April 12, 2021

Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting

PR Newswire April 12, 2021

IIROC Trade Resumption - ONC

Canada NewsWire April 9, 2021

IIROC Trading Halt - ONC

Canada NewsWire April 9, 2021

Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference

PR Newswire April 8, 2021

Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors

Canada NewsWire April 5, 2021

Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting

Canada NewsWire March 10, 2021

Oncolytics Biotech® Establishes New At-The-Market Facility

Canada NewsWire March 5, 2021

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

Canada NewsWire March 5, 2021

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights

Canada NewsWire February 26, 2021

Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies

Livemoney February 24, 2021

Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors

Canada NewsWire February 23, 2021

IIROC Trade Resumption - ONC

Canada NewsWire February 17, 2021

IIROC Trading Halt - ONC

Canada NewsWire February 17, 2021

Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium

Canada NewsWire December 9, 2020

New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)

Livemoney December 2, 2020

Ancient Aztec Medicine Could Be A Gamechanger For Mental Health

Livemoney November 30, 2020

Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting

Canada NewsWire November 19, 2020